As digitization becomes a necessity in the life sciences industry, Gb Sciences proves it’s already ahead of the curve with its own revolutionary technology.
Gb Sciences is a plant-inspired, biopharmaceutical research and drug development company that began building its proprietary digital research and analytics platform long before the pandemic sparked a digital transformation.
According to a study by Deloitte, biopharma lagged behind other industries in digital transformation. Eighty percent of survey respondents (including 150 executives from large biopharma companies) said they believe that their organization needs to be more aggressive and adopt digital technologies faster to win in the market. Gb Sciences’ Phytomedical Analytics for Research Optimization at Scale platform, or PhAROS™ for short, successfully uses data analytics and machine learning to accelerate the drug development research process in an effort to get novel, plant-inspired formulations to market faster.
PhAROS™ may be the best toolkit for discovering the “Future of Medicine”: a combination of Artificial Intelligence (AI) technology, traditional plant-based medicine, and hard science that allows researchers to explore and validate targeted mixtures of ingredients for the treatment of complex diseases. Typical medical studies have relied on simplified models of disease because the digital technology to interpret large, multivariate data sets had not been developed. Using AI and machine learning, biomedical research can push forward past simplistic approaches to treating human diseases as if a single “magic bullet” could cure a complex disease. Through our PhAROS™ platform, our researchers can identify suitably complex, multi-ingredient therapies for the treatment of complex human diseases.
Gb Sciences’ President and CSO, Dr. Andrea Small-Howard, says, “The use of AI and computer modeling for biomedical research presents an untapped opportunity to discover plant-inspired medicines reflecting the vast knowledge of traditional medicines, but simplified. PhAROS™ uses machine learning to identify potentially effective combinations of drugs amongst the known traditional medicine systems in a complex view of human diseases. The PhAROS™ platform yields numerous potentially effective, plant-inspired combination drugs to help millions worldwide and also pre-screens these drug candidates for potentially unwanted side effects.”
Digital technologies not only improve drug research and reduce production costs, they provide an advantage in supply chain stability, as Gb leverages PhAROS™ to find more readily available biosimilars of plants all over the world. Gb has used digital technology to discover its patent-pending formulations for anxiety, depression, chronic pain, Parkinson’s disease, COVID-cytokine release syndrome, and heart disease. Using sequential in silico, in vitro, and in vivo screens, Gb Sciences has identified unique and patentable subsets of plant components with therapeutic potential that were validated in cell and animal models.
Learn more by visiting www.gbsciences.com.
Visit AITechPark for cutting-edge Tech Trends around AI, ML, Cybersecurity, along with AITech News, and timely updates from industry professionals!
